HK1250646A1 - 納米粒子免疫偶聯物 - Google Patents

納米粒子免疫偶聯物

Info

Publication number
HK1250646A1
HK1250646A1 HK18110131.9A HK18110131A HK1250646A1 HK 1250646 A1 HK1250646 A1 HK 1250646A1 HK 18110131 A HK18110131 A HK 18110131A HK 1250646 A1 HK1250646 A1 HK 1250646A1
Authority
HK
Hong Kong
Prior art keywords
immunoconjugates
nanoparticle
nanoparticle immunoconjugates
Prior art date
Application number
HK18110131.9A
Other languages
English (en)
Inventor
Barney Yoo
Tom Quinn
Michelle Bradbury
Ulrich Wiesner
Jason Lewis
Kai Ma
Feng Chen
Original Assignee
Memorial Sloan Kettering Cancer Center
Univ Cornell
Univ Missouri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Univ Cornell, Univ Missouri filed Critical Memorial Sloan Kettering Cancer Center
Publication of HK1250646A1 publication Critical patent/HK1250646A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
HK18110131.9A 2015-04-07 2018-08-07 納米粒子免疫偶聯物 HK1250646A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144278P 2015-04-07 2015-04-07
US201562151943P 2015-04-23 2015-04-23
PCT/US2016/026434 WO2016164578A1 (en) 2015-04-07 2016-04-07 Nanoparticle immunoconjugates

Publications (1)

Publication Number Publication Date
HK1250646A1 true HK1250646A1 (zh) 2019-01-11

Family

ID=55806803

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110131.9A HK1250646A1 (zh) 2015-04-07 2018-08-07 納米粒子免疫偶聯物

Country Status (10)

Country Link
US (3) US10548989B2 (zh)
EP (1) EP3280454A1 (zh)
JP (2) JP6869187B2 (zh)
KR (1) KR20180002645A (zh)
CN (2) CN107735110B (zh)
AU (2) AU2016246737B2 (zh)
BR (1) BR112017020689A2 (zh)
CA (1) CA2980462C (zh)
HK (1) HK1250646A1 (zh)
WO (1) WO2016164578A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015020782A2 (pt) 2013-03-15 2017-10-10 Univ Cornell nanopartículas à base de sílica multimodal
EP3280454A1 (en) 2015-04-07 2018-02-14 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates
AU2016271040A1 (en) 2015-05-29 2017-11-23 Cornell University Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
JP7455510B2 (ja) 2016-04-29 2024-03-26 メモリアル スローン－ケタリング キャンサー センター 悪性脳腫瘍における標的化粒子の浸透、分布および応答のための組成物及び方法
JP2020500863A (ja) * 2016-11-30 2020-01-16 メモリアル スローン ケタリング キャンサー センター 阻害剤官能化超小型ナノ粒子およびその方法
NZ755835A (en) 2017-01-17 2023-12-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
KR102228571B1 (ko) * 2017-02-09 2021-03-16 주식회사 메디폴리머 정신질환 또는 중추신경계 질환 치료용 약물전달 제형
WO2018217528A1 (en) * 2017-05-25 2018-11-29 Memorial Sloan Kettering Cancer Center Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof
AU2019206623A1 (en) * 2018-01-12 2020-07-16 Prolynx Llc Synergistic cancer treatment
CN112135639B (zh) * 2018-04-06 2023-10-20 北卡罗莱纳州立大学 细胞组装介导的癌症免疫治疗检查点抑制剂的递送
EP3811054A1 (en) * 2018-06-21 2021-04-28 Codiak BioSciences, Inc. Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering
CN109490523A (zh) * 2018-10-22 2019-03-19 北京纳晶生物科技有限公司 用于标记的纳米材料、核酸探针及核酸与纳米材料偶联的方法
KR102336120B1 (ko) * 2019-06-05 2021-12-08 주식회사 엔이에스바이오테크놀러지 금 나노입자-앱타머 결합체를 기반으로 하는 항체 전달체 및 이의 제조 방법
WO2021054490A1 (ko) * 2019-09-18 2021-03-25 연세대학교 산학협력단 양친매성 고분자, 이를 포함하는 수분산성 금속나노입자 및 이의 제조방법
WO2021092065A1 (en) * 2019-11-04 2021-05-14 Cornell University Ultrasmall nanoparticles and methods of making, using and analyzing same
CN111906328B (zh) * 2020-08-11 2022-10-25 苏州大学 一种177Lu标记的金纳米团簇及其制备方法和应用
AU2021370647A1 (en) 2020-10-27 2023-06-08 Elucida Oncology, Inc. Folate receptor targeted nanoparticle drug conjugates and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
ATE349438T1 (de) 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
LT1507556T (lt) 2002-05-02 2016-10-10 Wyeth Holdings Llc Kalicheamicino darinio ir nešiklio konjugatai
KR20040106547A (ko) 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 비타민-마이토마이신 공액체
US20040101822A1 (en) * 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
WO2009045579A2 (en) * 2007-06-14 2009-04-09 The Regents Of The University Of California Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
US20080317768A1 (en) * 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
KR20230003298A (ko) 2008-04-30 2023-01-05 이뮤노젠 아이엔씨 가교제 및 그 용도
US20110274617A1 (en) * 2008-11-26 2011-11-10 National Research Council Of Canada Antibody-Targeted Carrier For Contrast Agents
PT3903829T (pt) 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
DK2449379T3 (en) 2009-07-02 2017-08-28 Sloan-Kettering Inst For Cancer Res FLUORESCING SILICA-BASED NANOPARTICLES
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
CN106432557A (zh) * 2010-04-15 2017-02-22 科迪亚科学企业公司 高分子量的含两性离子的聚合物
BR112015020782A2 (pt) 2013-03-15 2017-10-10 Univ Cornell nanopartículas à base de sílica multimodal
EP3280454A1 (en) 2015-04-07 2018-02-14 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates

Also Published As

Publication number Publication date
KR20180002645A (ko) 2018-01-08
CA2980462A1 (en) 2016-10-13
AU2016246737B2 (en) 2019-11-21
BR112017020689A2 (pt) 2018-06-26
US10548989B2 (en) 2020-02-04
JP2021073271A (ja) 2021-05-13
JP6869187B2 (ja) 2021-05-12
CN107735110B (zh) 2021-11-26
US20230037294A1 (en) 2023-02-09
WO2016164578A1 (en) 2016-10-13
US20180133342A1 (en) 2018-05-17
CN107735110A (zh) 2018-02-23
AU2016246737A1 (en) 2017-10-12
EP3280454A1 (en) 2018-02-14
JP7016975B2 (ja) 2022-02-07
CA2980462C (en) 2023-08-01
AU2019271919A1 (en) 2019-12-19
AU2019271919B2 (en) 2021-10-28
JP2018516854A (ja) 2018-06-28
US20200353096A1 (en) 2020-11-12
CN113876962A (zh) 2022-01-04

Similar Documents

Publication Publication Date Title
HK1250646A1 (zh) 納米粒子免疫偶聯物
IL285516B (en) Amatoxin antibody conjugates
IL250461A0 (en) Anti-cll-1 antibodies and immunoconjugates
HK1255141A1 (zh) 包含抗folr1免疫綴合物的治療組合
PL3148591T3 (pl) Koniugaty nanocząstka-lek
HK1255483A1 (zh) 抗體和免疫結合物
GB201513607D0 (en) Pyrrolobenzodiazepine-antibody conjugates
SG11201710198YA (en) Anticancer agent
GB201421161D0 (en) Metal complex formulations
HK1250237A1 (zh) Il22免疫綴合物
GB201503603D0 (en) SERS active nanoparticles
IL281425A (en) Nanoparticle formulations
IL252488B (en) A phase change nanoparticle
GB201412824D0 (en) Nanoparticles
GB201615688D0 (en) Nanomaterial
GB201601004D0 (en) Nanoparticle conjugates
HK1257229A1 (zh) Cck2r-藥物偶聯物
GB201509934D0 (en) Nanoparticles
HK1253336A1 (zh) 吲哚並吡咯啉抗腫瘤藥物
GB201610642D0 (en) Nanoparticles
PT3270711T (pt) Conjugados açúcar-dipéptido
SG10201506686WA (en) Conjugates
GB201604220D0 (en) Nanoparticles
GB201520637D0 (en) Nanoparticles
GB201521470D0 (en) IL22 immunoconjugates